MENU
AKBA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

AKBA stock forecast, quote, news & analysis

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 11, 2026

Why Akebia Therapeutics (AKBA) Stock Is Down -33% in the Last 30 Days

Key Takeaways

  • AKBA shares fell roughly 33% over the last 30 days, sliding from about $0.79 to approximately $0.53 as investors digested a sharp third-quarter earnings miss.
  • Third-quarter 2026 revenue of $36.9 million missed consensus estimates and declined about 37% year over year, pressured by generic competition for Auryxia.
  • Vafseo (vadadustat) underlying demand remains solid — patients on therapy grew roughly 140% year over year to about 11,500 — but channel inventory drawdowns weighed on reported net product revenue.
  • Positive topline VOCAL trial data showed three-times-weekly vadadustat was non-inferior to ESAs in maintaining hemoglobin, while VOICE results pointed to fewer hospitalizations.
  • Analysts at H.C. Wainwright and BTIG trimmed price targets but kept Buy ratings after the quarter, signaling a more cautious near-term outlook.
  • For additional detail on valuation and fundamentals, review Akebia's Price Targets, Earnings, and Forecast pages.
  • Investors can also explore Trending AI Robots for automated, data-driven trading strategies across the market.

Akebia Therapeutics (AKBA) Company Overview and Market Position

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease. Founded in 2007 and headquartered in the Cambridge/Waltham, Massachusetts area, the company went public on Nasdaq in March 2014. Its commercial portfolio centers on two products: Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in the U.S. in March 2024 for anemia due to chronic kidney disease (CKD) in adults on dialysis, and Auryxia (ferric citrate), used to control serum phosphorus levels in dialysis-dependent CKD and to treat iron deficiency anemia in non-dialysis-dependent CKD.

Vafseo launched commercially in the U.S. in January 2025 and is approved in dozens of countries globally. Akebia's pipeline includes praliciguat for focal segmental glomerulosclerosis (FSGS), AKB-097 for complement-mediated rare kidney diseases, and earlier-stage HIF-based candidates. The company generates revenue through product sales and through partnerships with Mitsubishi Tanabe in Japan, Medice in Europe, and other collaborators. Investors follow AKBA for its exposure to the large CKD market, the commercial ramp of Vafseo, and the development of its rare-kidney-disease franchise.

Akebia Therapeutics (AKBA) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, AKBA has fallen approximately 33%, declining from a closing price of about $0.79 to roughly $0.53. The decline was not gradual: most of the damage occurred in a single session around the November 5 third-quarter earnings release, when the stock dropped from about $0.69 to roughly $0.43, a decline of nearly 39% in one day.

The longer-term trend has been even weaker. Over the last quarter, shares have declined roughly 39%, falling from about $0.87 in mid-August to approximately $0.53. The stock has traded within a wide 52-week range of about $0.36 to $1.89, reflecting sustained volatility and a meaningful repricing of the company's near-term growth prospects.

What Drove AKBA Stock Price in the Last 30 Days

The dominant catalyst behind the recent selloff was Akebia's third-quarter 2026 financial report, released on November 5. The company posted revenue of $36.9 million, missing consensus estimates by a wide margin and down about 37% from $58.8 million a year earlier. Adjusted EPS of a loss of $0.05 also missed expectations, and the company swung to a net loss of about $14.4 million from a small profit a year earlier.

Two factors drove the revenue shortfall. First, Auryxia revenue fell to roughly $20 million from about $42.5 million in the prior-year quarter as generic competition eroded sales. Second, while Vafseo's patient base expanded about 140% year over year, reported Vafseo net product revenue rose only about 3% to $14.8 million because customers drew down inventory ahead of the product's January 1, 2027 TDAPA expiration. Management also cited lower-than-expected average dosing and dialysis adherence.

Partly offsetting the disappointing results, Akebia reported positive topline data from the VOCAL trial, showing that three-times-weekly vadadustat met its primary endpoint of non-inferiority to erythropoiesis-stimulating agents (ESAs) in maintaining hemoglobin. VOICE data presented at a recent conference showed fewer hospitalizations versus ESAs. Following the quarter, analysts at H.C. Wainwright and BTIG lowered their price targets but maintained Buy ratings, reflecting the tension between near-term headwinds and the product's longer-term potential.

What Drove AKBA Stock Performance Over the Last Quarter

AKBA's quarterly decline reflects a broader narrative of commercial transition and investor recalibration. Auryxia, once a core revenue driver, lost U.S. exclusivity and has faced expanding generic competition, pressuring a key profit stream. At the same time, Vafseo's commercial trajectory, while encouraging on a patient-count basis, has been complicated by inventory dynamics and the approaching end of its transitional drug add-on payment adjustment (TDAPA) period at the start of 2027.

Sentiment deteriorated through the fall as investors weighed slower-than-expected conversion of patient demand into reported revenue and uncertainty over post-TDAPA pricing and reimbursement. Positive clinical data — including VOCAL topline results and VOICE outcomes — provided fundamental support but were not enough to offset the revenue disappointment and the company's shift back to quarterly losses. The result has been a sustained downward repricing of the stock over the past three months.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. While Tickeron offers hundreds of AI-driven trading bots that monitor thousands of tickers across a range of markets, only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, allowing traders to compare approaches that fit different risk profiles and horizons. The page provides a neutral, data-focused way to observe how algorithmic models are positioning across equities and other assets. Investors interested in supplementing their own analysis with systematic, rule-based signals may find the section a useful starting point for further research.

AKBA Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors are likely to shape AKBA's trajectory. The most immediate is Vafseo's transition past the January 1, 2027 TDAPA expiration, where post-transition pricing and the pace of adoption by large dialysis organizations will be closely watched. Management has guided to continued patient growth, but inventory normalization and reimbursement changes could keep near-term revenue volatile.

Investors should also monitor Auryxia's exposure to further generic erosion, the company's cash position of roughly $159 million, and its stated ability to fund operations for at least two years. Clinical milestones in the rare-kidney-disease pipeline — including Phase 2 programs for praliciguat and AKB-097 — and any refinancing of the senior secured term loan represent additional catalysts. As always, these developments carry execution and regulatory risk, and investors should conduct their own due diligence rather than rely on any single forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for AKBA with price predictions
Nov 20, 2026

AKBA's RSI Oscillator recovers from oversold territory

The RSI Oscillator for AKBA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 32 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 223 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In 64 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for AKBA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 38 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for AKBA entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.445) is normal, around the industry mean (6.379). P/E Ratio (-3.344) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (183.387).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 62
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
Why Akebia Therapeutics (AKBA) Stock Is Down -33% in the Last 30 Days